Schizophrenia
Conditions
Brief summary
The purpose of this study is to examine the clinical therapeutic dose in Japanese agitated patients with schizophrenia.
Interventions
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients at least 20 years of age and less than 65 years old * Patients must be inpatients during the study * Patients must have a diagnosis of schizophrenia as per the DSM-IV, as determined by the investigator * Patients must be considered by the investigator to be clinically agitated and to be clinically appropriate candidates for the treatment with intramuscular (IM) medication * Patients must have a minimum total score of greater than or equal to 14 on the 5 items of the PANSS-EC and at least one individual item score of greater than or equal to 4 using the 1-7 scoring system, prior to the first IM injection of study drug
Exclusion criteria
* Serious, unstable illnesses such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months. This includes hepatic (specifically any degree of jaundice), renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic diseases * Known history of seizures; however, a patient whose etiology is identifiable and has been resolved may be enrolled * Known history of diabetes mellitus, complications of diabetes mellitus, or potential diabetes mellitus as defined by patients with single blood glucose measurement based on site tests; patients with values greater than or equal to 140 mg/dL (non-fasting) or greater than or equal to 110 mg/dL (fasting) must be excluded from the study * History of allergic reaction or intolerance to olanzapine * Have received treatment with psychostimulants or reserpine within 1 week prior to study drug administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to examine the safety and efficacy of the clinical therapeutic dose of IM olanzapine (7.5 mg/inj and 10 mg/inj) in Japanese agitated patients with schizophrenia | — |
Secondary
| Measure | Time frame |
|---|---|
| To examine the efficacy of IM olanzapine by evaluating change from baseline to 24 hours following the first IM injection in the PANSS Excited Component Total Score and the ACES | — |
| To examine the characteristics of sedation for each treatment group based on the ACES score | — |
| To examine a frequency of patients who needed second injection | — |
Countries
Japan
Outcome results
None listed